Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. by Yoganathan, Priyatharsan et al.




of polymorphisms within the gene locus 
of NOD-like receptor pyrin domain containing 3 
in Swiss inflammatory bowel disease patients
Priyatharsan Yoganathan1, Jean‑Benoit Rossel2, Sebastian Bruno Ulrich Jordi1,3, Yannick Franc2, 
Luc Biedermann1, Benjamin Misselwitz1,3, Martin Hausmann1, Gerhard Rogler1,4, Michael Scharl1,4 and 
Isabelle Frey‑Wagner1,5,6* Swiss IBD cohort study group 
Abstract 
Background: Genetic variations within the regulatory region of the gene encoding NOD‑like receptor pyrin domain 
containing 3 (NLRP3) have been associated with Crohn’s Disease (CD). NLRP3 is part of the NLRP3‑inflammasome that 
mediates the maturation of IL‑1β and IL‑18. Carrying the major allele of the single nucleotide polymorphisms (SNPs) 
rs10733113, rs4353135 and rs55646866 is associated with an increased risk for CD. We here studied the impact of 
these polymorphisms on clinical characteristics in patients of the Swiss IBD Cohort Study (SIBDCS).
Methods: We included 981 Crohn’s disease (CD) patients and 690 ulcerative colitis (UC) patients of the SIBDCS. We 
analyzed whether three CD‑associated NLRP3 polymorphisms have an impact on the clinical disease course in these 
patients.
Results: In CD patients presence of the major allele (G) of rs10733113 was associated with less surgeries and lower 
maximal CDAI and a similar trend was observed for rs55646866 and rs4353135. Presence of the major allele of all three 
SNPs was negatively correlated to maximal CDAI. In UC patients homozygous genotype for the major allele (CC) for 
rs55646866 was associated with a higher age at diagnosis and a higher MTWAI index. Homozygous genotype for the 
major allele of all three polymorphisms was associated with a higher number of ambulatory visits and longer hospital 
stays.
Conclusions: In CD patients presence of the major allele of all three polymorphisms was associated with markers 
of a less severe disease course, while in UC the homozygous genotype for all major alleles suggested a more severe 
disease activity.
Keywords: NLRP3 inflammasome, Inflammatory bowel disease, Single nucleotide polymorphisms, Clinical 
characteristics
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Background
Genetic variations in a predicted regulatory region of the 
NOD-like receptor pyrin domain containing 3 (NLRP3) 
gene locus have been associated with an increased risk 
to develop Crohn’s disease (CD) [1]. CD risk has been 
linked to the major alleles of the NLRP3 single nucleotide 
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polymorphisms (SNPs) rs10733113, rs4353135 and 
rs55646866; however, 64–85% of the healthy European or 
Canadian population carry the disease-associated alleles 
[1]. For an overview of the major allele frequency in dif-
ferent populations and for details on SNP location see 
Additional file 2: Table S1 and Additional file 1: Figure S1.
The protein NLRP3 belongs to the family of nucleo-
tide binding oligomerization domain (NOD) and leu-
cine rich repeat (LRR) containing receptors (NLRs). It 
has an important role in the innate immune response, 
namely sensing of pathogen associated molecular pat-
terns (PAMPs) and danger associated molecular patterns 
(DAMPs).
Upon activation, NLRP3 assembles with pro-caspase-1 
and apoptosis-associated speck-like protein (ASC) to 
the NLRP3 inflammasome, resulting in autoproteolytic 
cleavage of pro-caspase-1 to active caspase-1 (CASP1). 
CASP1 is responsible for the conversion of pro-inter-
leukin (IL)-1β and pro-IL-18 to the active cytokines [2]. 
Inflammatory bowel disease (IBD) patients tend to have 
higher levels of these cytokines in the serum [3]. Elevated 
secretion of IL-1β by lamina propria mononuclear cells 
isolated from inflamed IBD patients has been reported 
in several studies [4–6], and IL-1β levels in colonic per-
fusion fluid correlated with disease activity [7] or risk of 
relapse within the next year [8]. Yet, experimental colitis 
in mice deficient in NLRP3 could not prove an unequivo-
cal pro-inflammatory role of NLRP3. Depending on the 
animal model, environment and hygienic conditions, lack 
of NLRP3 either ameliorated or aggravated experimental 
colitis [9–12].
So far, little is known about the functional conse-
quences of human NLRP3 associated genetic variants. 
The major alleles of rs4353135 and rs10733113 have 
been shown to lead to lower NLRP3 mRNA expression in 
human peripheral blood mononuclear cells (PBMCs) [1, 
13]. The major allele (GG) of rs6672995 was associated 
with lower IL-1β secretion from stimulated PBMC [1], 
suggesting that the NLRP3 polymorphisms that are asso-
ciated with CD might lead to lower NLRP3-inflammas-
ome activity. In line with the proposed pro-inflammatory 
role of the NLRP3 inflammasome during established 
IBD, polymorphisms that affect NLRP3 activity might 
also affect the clinical course of IBD patients, but such a 
relationship has not been addressed, so far.
We here studied for the first time whether the CD 
associated variants of the three SNPs (rs10733113, 
rs55646866, rs4353135) located in a regulatory region 
on chromosome 1q44 downstream of NLRP3 affect the 
disease characteristics in IBD patients of the Swiss IBD 
cohort study (SIBDCS). In CD patients, the major allele 
of all three SNPs was negatively correlated to maxi-
mal CDAI, suggesting a less severe course of disease. In 
contrast, in UC patients, presence of the major allele of 
rs55646866 was associated with a higher MTWAI while 
homozygous genotype for the major allele of all three 
polymorphisms was associated with a higher number 
of ambulatory visits. Our findings might lead to a bet-
ter understanding of disease pathogenesis depending on 
NLRP3 genotype and identify patients that might benefit 
from a NLRP3 targeted therapy.
Methods
Patient data
Data were obtained from the nationwide Swiss Inflamma-
tory Bowel Disease Cohort Study (SIBDCS). The SIBDCS 
is a prospective multicenter observational population-
based study into which patients with IBD from all regions 
of Switzerland have been included since 2006. The goals 
and the methodology of the cohort have been described 
in detail previously [14, 15].
Study design
We included 1671 IBD patients (981 CD and 690 UC) 
that were enrolled in the SIBDCS at time of data acqui-
sition and had been genotyped for the CD-associated 
single nucleotide polymorphisms (SNP) rs4353134, 
rs55646866 and rs10733113 within a regulatory region 
on chromosome 1q44 downstream of the NLRP3 gene. 
Genotyping was performed as part of an analysis of 
the whole SIBDCS for selected SNPs that are currently 
known to be associated with IBD [16]. SNP Genotyping 
of SIBDCS samples was performed by MALDI-TOFF 
based analysis [17].
The aim of this study was to analyze whether the CD-
associated risk variants for NLRP3 rs4353134, rs55646866 
and rs10733113 are associated with clinical parameters 
defining the severity/course of disease. For rs4353134, 
the T-allele is the major allele and the G-allele the minor 
allele. The major and minor alleles for rs55646866 are 
C/T and for rs10733113 G/A, respectively.
For analysis of clinical characteristics, we included 
gender, diagnosis, age at diagnosis, disease duration, 
complications, Crohn’s disease activity index (CDAI) or 
modified Truelove and Witts activity index (MTWAI), 
reported flare (including possible cause of flare, flare 
management and hospitalization), fistula, abscess or anal 
fissure, stenosis, presence of extraintestinal manifesta-
tions, intestinal surgery and medication.
Statistical analysis
Clinical data were obtained from the data center of the 
SIBDCS at the University of Lausanne. These data and 
additional data obtained from a review of the patients’ 
files were entered into a database (Access 2000; Micro-
soft Switzerland Ltd Liab. Co., Wallisellen, Switzerland). 
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Stata 14 software (StataCorp, 2015, College Station, TX 
was used for the statistical analysis.
We analyzed for associations between clinical char-
acteristics and genotype for rs4353135, rs55646866 and 
rs10733113 with Fisher’s exact test for discrete vari-
ables and with the Kruskal–Wallis test for continuous 
variables. To analyze for a cumulative risk of the three 
variants, we calculated a score based on the odds ratio 
for the risk allele as described by Villani et al. [1] for all 
patients (Score = x * log(OR rs4353135 T-allele) + y * 
log(OR rs55646866 C-allele) + z * log (OR rs10733113 
G-allele); x, y, z = number of major allele (0, 1 or 2)) 
resulting in a score between 0 and 2.58 for each patient. 
We performed  linear regression analyses with this 
score as predictor and clinical parameters as response. 
Log(maxCDAI) was used for the analysis to reduce the 
impact of very high values.
For calculation of linkage disequilibrium (LD) we used 
the square of the correlation coefficient  (r2) between 
SNP pairs (R, genetics package, with the function LD()) 
https:// doi. org/ 10. 1086/ 381000 [1].
Results
In this study, we investigated a total of 1671 IBD patients 
of the SIBDCS. 981 (58.7%) patients were classified as CD 
and 690 (41.3%) as UC patients.
Distribution of NLRP3 SNP genotypes in CD and UC 
patients
The distribution of the alleles for rs4353135, rs55646866 
and rs10733113713 and the joint distribution of alleles 
in CD and UC patients are presented in Tables 1 and 2. 
There were no significant differences in distribution of 
the genotypes between CD and UC patients. The major 
allele frequency in SIBDCS patients was 0.68 (T) for 
rs4353135, 0.89 (C) for rs55646866, and 0.74 (G) for 
rs10733113713, corresponding well with the major allele 
frequency in the European population. For an overview 
of the major allele frequencies in different populations 
see Additional file 2: Table S1. 422 (43.0%, CD) and 285 
(41.3%, UC) patients are homozygous carriers for the 
major allele of all three SNPs. As CD and UC are distinct 
forms of IBD with diverging disease pathogenesis, we 
performed individual analyses for associations between 
NLRP3 SNPs and disease characteristics in CD and UC 
patients.
Presence of the major allele of all three SNPs is associated 
with lower maximal CDAI in CD patients
Presence of the major allele (G) of rs10733113 was asso-
ciated with a significantly lower maximal CDAI value 
throughout follow-up (median CDAI = 63 in GG or AG 
vs. 76 in AA patients, p = 0.011, and we observed simi-
lar trends, yet not significant, for lower CDAI in car-
riers of the major alleles of rs4353135 and rs55646866 
(Fig.  1A). The investigated SNPs have been reported to 
be linked due to close proximity of their loci [1] (they 
all lie within a 5321 bp region, for details see Additional 
file  1: Figure S1). In our cohort, however, the square of 
the correlation coefficient  r2 (Additional file 2: Table S2) 
was below 0.2, suggesting no relevant linkage of the stud-
ied SNPs. To analyze whether there is an additive effect 
Table 1 Cross table of joint SNP distribution in CD patients
rs10733113 Total
GG AG AA
rs4353135: TT 423 (90.8%) 1 (0.2%) 42 (9.0%) 466 (100%)
GT 252 (61.5%) 5 (1.2%) 153 (37.3%) 410 (100%)
GG 38 (36.2%) 1 (0.9%) 66 (62.9%) 105 (100%)
Total 713 (72.7%) 7 (0.7%) 261 (26.6%) 981 (100%)
rs55646866: CC 710 (90.4%) 3 (0.4%) 72 (9.2%) 785 (100%)
CT 3 (1.7%) 4 (2.3%) 166 (96.0%) 173 (100%)
TT 0 (0%) 0 (0%) 23 (100%) 23 (100%)
Total 713 (72.7%) 7 (0.7%) 261 (26.6%) 981 (100%)
rs4353135 Total
TT GT GG
rs55646866: CC 465 (59.2%) 282 (35.9%) 38 (4.8%) 785 (100%)
CT 1 (0.6%) 128 (74.0%) 44 (25.4%) 173 (100%)
TT 0 (0%) 0 (0%) 23 (100%) 23 (100%)
Total 466 (47.5%) 410 (41.8%) 105 (10.7%) 981 (100%)
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on the association between NLRP3 SNPs and clinical 
parameters, we calculated a score for the cumulative 
genetic risk for carrying the major allele of all 3 poly-
morphisms. To calculate this score we added the log of 
the odds ratio (as identified by Villani et  al. [1]) for the 
CD associated allele of the given SNP (log (1.78) = 0.58 
for rs10733113, log (1.21) = 0.19 for rs43353135, log 
(1.69) = 0.52 for rs55646866) resulting in a score between 
0 and 2.58 for each patient. In a linear regression model 
with this genetic score as predictor and log (max. CDAI) 
as response we observed a significant negative asso-
ciation (Coefficient − 0.097; 95% CI − 0.182 to − 0.011; 
p = 0.026), indicating that carrying the CD-associated 
alleles for the 3 investigated NLRP3 SNPs is associated 
with a less severe course of disease as evaluated by dis-
ease symptoms (Fig. 1B), and that there might be an addi-
tive effect of the three SNPs.
Carrying the major allele for rs55646844 is associated 
with longer disease duration in CD patients
Duration of disease, the time from diagnosis until last 
patient visit (i.e., the most recent patient visit, either at 
the regular yearly visit for the SIBDCS or the latest dis-
ease associated visit) 
was significantly longer in patients carrying the 
major allele for rs55646866 (12.3  years for CC or CT 
vs. 6.1  years for TT, p = 0.013). For rs4353135 a similar 
trend, yet not significant, could be observed (12.4  years 
for GT or TT vs. 9.9 years for GG, p = 0.090) while there 
was no effect for rs10733113. Yet, age at diagnosis was 
not affected by the genotype for rs55646844 (Fig. 1C).
The major allele (GG) for rs10733113 is associated 
with fewer operations due to stenosis in CD patients
While the overall incidence of stenosis did not differ 
between genotypes, homozygous carriers of the major 
allele (GG) for rs10733113 had significantly less opera-
tions for treatment of stenosis (153 (49.4%) in GG, 0 (0%) 
in AG, 68 (58.1%) in AA, p = 0.045). The genotype of the 
SNPs rs4353235 and rs55646866 was not associated to the 
frequency of operations needed for treatment of stenosis 
(Fig. 1D).
NLRP3 SNPs are not associated with further clinical disease 
characteristics in CD patients.
The major alleles of rs10733113, rs4353235 and rs55646866 
were associated with a lower maximal CDAI value, suggest-
ing a less severe course of disease in carriers of the major 
alleles. We analyzed whether individual clinical character-
istics e.g. flare frequency, extraintestinal manifestations or 
medication are associated with carrying the major allele of 
the investigated polymorphisms. No further associations 
between genotype for rs10733113, rs4353235, rs55646866 
and disease characteristics were observed in CD patients. 
Tables 3, 4 and 5 show the demographic distribution and 
clinical characteristics investigated for the different geno-
types of rs10733113, rs4353235 and rs55646866.
Carrying the major alleles for rs10733113, rs4353235 
and rs55646866 is associated with a higher number 
of ambulatory hospitalizations in UC patients
Additional ambulatory visits are strong indicators for 
occurrence of a moderate to severe flare in UC patients. 
Table 2 Cross table of joint SNP distribution in UC patients
rs10733113 Total
GG AG AA
rs4353135: TT 286 (90.2%) 3 (1.0%) 28 (8.8%) 317 (100%)
GT 196 (65.5%) 11 (3.7%) 92 (30.8%) 299 (100%)
GG 34 (45.9%) 0 (0%) 40 (54.1%) 74 (100%)
Total 516 (74.8%) 14 (2.0%) 160 (23.2%) 690 (100%)
rs55646866: CC 514 (90.7%) 4 (0.7%) 49 (8.6%) 567 (100%)
CT 2 (1.8%) 10 (9.0%) 99 (89.2%) 111 (100%)
TT 0 (0%) 0 (0%) 12 (100%) 12 (100%)
Total 516 (74.8%) 14 (2.0%) 160 (23.2%) 690 (100%)
rs4353135 Total
TT GT GG
rs55646866: CC 316 (55.7%) 216 (38.1%) 35 (6.2%) 567 (100%)
CT 1 (0.9%) 82 (73.9%) 28 (25.2%) 111 (100%)
TT 0 (0%) 1 (8.3%) 11 (91.7%) 12 (100%)
Total 217 (45.9%) 299 (43.3%) 74 (10.7%) 690 (100%)
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Homozygous genotype for the major allele of all three 
polymorphisms was associated with a higher number of 
ambulatory visits for flare management in UC patients 
(Fig.  2A). Despite their close proximity and earlier 
reports of linkage disequilibrium, the investigated poly-
morphisms showed low linkage disequilibrium in the 
SIBDCS (Additional file 2: Table S2) and we observed a 
significant association between the number of risk-asso-
ciated alleles and the number of visits. We applied the 
same genetic score as calculated for the cumulative effect 
of all three SNPs on CDAI in CD patients for analysis of 
ambulatory flare management in UC patients. Based on a 
logistic regression, we find that this score is significantly 
associated with the occurrence of at least one ambulatory 
flare measure (OR: 2.081 (95% CI 1.393–3.111; p < 0.001)) 
(Fig. 2B).
Homozygous genotype for the major allele (CC) 
of rs55646866 is associated with a higher age at disease 
onset and a higher MTWAI index
The MTWAI index characterizes the severity of disease 
as defined by symptoms in UC patients. Homozygous 
genotype (CC) for rs55646866 was associated with a 
higher MTWAI index in UC patients (mean MTWAI: 5 
(CC), 5 (CT), 1.5 (TT), p = 0.009). We further observed 




individual SNPs on 
maximal CDAI
*
Fig. 1 Effect of the major alleles of rs10733113, rs4353135 and rs55646866 on clinical parameters in CD patients. The graphs show median Log 
(max. CDAI) values for maximal CDAI within the 25% and 75% percentile (box borders) and outliers (dots) in CD patients A homozygous for the 
major allele, heterozygous or homozygous for the minor allele for rs10733113, rs4353135 and rs55646866, B depending on the cumulative genetic 
risk score for carrying the major allele for rs1073313, rs4353135 and rs55646866. In a linear regression model, a significant negative correlation 
between the cumulative genetic score and log (max. CDAI) can be observed (Coefficient − 0.097; 95% CI − 0.182 to − 0.011; p = 0.026) C CD 
duration in months within the 25% and 75% percentile (box borders) and outliers (dots) and D percentage of patients with stenosis that required 
an operation for treatment of stenosis in CD patients homozygous for the major allele, heterozygous or homozygous for the minor allele for 
rs10733113, rs4353135 and rs55646866
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 Male (n = 488) 363 (50.9%) 4 (57.1%) 121 (46.4%) 0.390
 Female (n = 493) 350 (49.1%) 3 (42.9%) 140 (53.6%)
Age at diagnosis [years]
 Median, q25–q75, 24.7, 18.1–34.8, 21.3, 15.3–32.2, 23.4, 17.6–32.1, 0.164
 Min–max 1.1–81.4 9.0–40.1 0.8–81.0
Disease duration [years]
 Median, q25–q75, 12.1, 7.0–20.7, 7.5, 5.4–16.9, 12.7, 6.8–23.5, 0.462
 Min–max 0.1–56.6 3.4–20.5 0.3–52.4
Complications*
 No (n = 345) 259 (36.3%) 4 (57.1%) 82 (31.4%) 0.185
 Yes (n = 636) 454 (63.7%) 3 (42.9%) 179 (68.6%)
Fistula, abscess or anal fissure*
 No (n = 518) 376 (52.7%) 4 (57.1%) 138 (52.9%) 1.000
 Yes (n = 463) 337 (47.3%) 3 (42.9%) 123 (47.1%)
Focus on the “yes”:
 Perianal fistula 180 (53.4%) 3 (100%) 60 (48.8%) 0.214
 Other fistula 129 (38.3%) 1 (33.3%) 53 (43.1%) 0.686
 Fissure 102 (30.3%) 1 (33.3%) 37 (30.1%) 1.000
 Abscess 184 (54.6%) 1 (33.3%) 68 (55.3%) 0.779
 Surgery for fistula 178 (52.8%) 1 (33.3%) 67 (54.5%) 0.753
Stenosis*
 No (n = 551) 403 (56.5%) 4 (57.1%) 144 (55.2%) 0.916
 Yes (n = 430) 310 (43.5%) 3 (42.9%) 117 (44.8%)
Focus on the “yes”:
 Operation 153 (49.4%) 0 (0%) 68 (58.1%) 0.045
 Dilation 117 (37.7%) 2 (66.7%) 50 (42.7%) 0.359
 No intervention 170 (54.8%) 1 (33.3%) 65 (55.6%) 0.772
CDAI**—maximal value throughout follow-up
 Median, q25–q75, 63, 28–112, 73, 20–76, 76, 33–129, 0.024
 Min–max 2–435 6–81 0–479
Reported flare*
 No (n = 477) 355 (49.8%) 4 (57.1%) 118 (45.2%) 0.369
 Yes (n = 504) 358 (50.2%) 3 (42.9%) 143 (54.8%)
Flare possibly or highly related to (focus on yes):
 NSAIDs 9 (2.5%) 0 (0%) 2 (1.4%) 0.753
 Antibiotics 8 (2.2%) 0 (0%) 1 (0.7%) 0.485
 GI tract infection 54 (15.1%) 0 (0%) 30 (21.0%) 0.203
 Other infection 23 (6.4%) 0 (0%) 14 (9.8%) 0.357
 Treatment decr./disc 89 (24.9%) 1 (33.3%) 44 (30.8%) 0.338
 Other medication 4 (1.1%) 0 (0%) 3 (2.1%) 0.437
Flare management (focus on the yes):
 Hospitalization 61 (17.0%) 1 (33.3%) 24 (16.8%) 0.598
 Ambulatory 88 (24.6%) 0 (0%) 41 (28.7%) 0.468
 Surgery 37 (10.3%) 0 (0%) 13 (9.1%) 0.813
 Drug therapy 308 (86.0%) 3 (100%) 127 (88.8%) 0.650
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rs55646866 was associated with a higher age at diagno-
sis (mean age at diagnosis: 28 (CC), 30 (CT), 18.3 (TT), 
p = 0.004) (Fig. 2C).
NLRP3 SNPs are not associated with further clinical disease 
characteristics in UC patients.
The major alleles of rs10733113, rs4353235 and 
rs55646866 were associated with a higher number of 
ambulatory hospitalizations for flare management, sug-
gesting a more severe course of disease in carriers of 
the major alleles. We therefore investigated whether 
individual clinical characteristics, e.g. flare frequency, 
extraintestinal manifestations or medication, that are 
usually affected during a more severe disease course, are 
associated with carrying the major allele for rs10733113, 
rs4353235 and rs55646866. No further associations 
between homozygous genotype for the major allele of 
rs10733113, rs4353235, rs55646866 and disease charac-
teristics were observed in UC patients. Tables  6, 7 and 
8 show the demographic distribution and clinical char-
acteristics investigated for the different genotypes of 
rs10733113, rs4353235 and rs55646866.
Discussion
Polymorphisms in the regulatory region of NLRP3 have 
been associated with an increased risk to develop CD, yet 
the impact of these variants on established IBD has not 
been clarified, so far. We here analyzed for possible asso-
ciations between the SNPs rs10733113, rs4353135 and 
rs55646866 and the clinical characteristics of patients 
from the SIBDCS. Homozygous genotype for the major 
allele for rs10733113 was associated with a lower CDAI 
in CD patients. The same trend could be observed 
for rs4353135 and rs55646866. The SNPs rs4353135, 
rs55646866 and rs10733113 are in close proximity in the 
downstream region of NLRP3. Possible linkage disequi-
librium between SNP pairs has been reported previously 
[1]: while D’ values indicated linkage disequilibrium for 
all SNP pairs,  r2 showed very low linkage for 2 of the 3 
SNP pairs. However, our calculations of  r2 values with 
SIBDCS data showed no indication of substantial linkage 
disequilibrium among the three studied SNPs. Further-
more, linear regression models showed log-additive allele 
effects on maximal CDAI, suggesting independent effects 
of SNPs’ alleles Similarly, additive effects and a better 
diagnostic value of a genetic risk score in comparison to 
individual SNPs have recently been reported by Cleynen 
et al. [18]. As the CDAI describes the disease activity in 
CD patients, our findings suggest that the investigated 
CD-associated NLRP3 variants are associated with a 
less severe course of disease. In addition, homozygous 
genotype for the major allele for rs10733113 was asso-
ciated with fewer operations due to stenosis supporting 
our finding of an overall less severe course of disease in 
patients of this genotype.
The investigated polymorphisms in the regulatory 
region of NLRP3 had been associated to CD, only, but 
not to UC [1]. Still, as similarly elevated IL-1β levels have 
been reported for UC patients, suggesting that altera-
tions in NLRP3 inflammasome activity and IL-1β levels 
might also affect clinical disease characteristics in UC 
patients, UC patients were also included in our analysis. 
In contrast to CD, UC patients homozygous for the major 
allele of the studied NLRP3 polymorphisms seem to have 
a more severe course of disease. Homozygous genotype 
for all three polymorphisms was significantly associated 
with more days of hospitalization indicating most likely 
an acute flare. Again, the association with all three SNPs 
could not be explained by linkage disequilibrium, as we 
observed an additive risk for the genetic risk score for the 
number of ambulatory visits and did not find  r2 values 
indicative for linkage disequilibrium of these SNPs in the 
SIBDCS. In addition, homozygous genotype (GG) for the 
major allele of rs55646866 was associated with a higher 
MTWAI. As the MTWAI characterizes disease sever-
ity in UC patients, this finding further suggests a more 
severe course of disease in UC patients with GG geno-
type. In contrast, this genotype was associated with a 
higher age at diagnosis of disease. Higher age at diagnosis 
might suggest that the GG variant of rs55646866 is pro-
tective against development of UC, but we observed no 
further results that would support such a finding.
Further clinical characteristics, e.g. other parameters 
indicative of more severe disease like type of medica-
tion or need of treatment intensification, effects on CRP 








p value (Fisher 
or Kruskal–
Wallis)
Focus on the hospitalizations:
 Total days of hosp. 7, 2–17, 0, 0–0, 4.5, 1–13.5, 0.386
 Median, q25–q75, 0–55 0–0 0–86
 Min–max
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Table 5 Demographic and clinical characteristics for the different genotypes of rs55646866 in CD patients
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affected by NLRP3 variants, neither in CD nor in UC 
patients.
Genetic determination of high interindividual varia-
tion of in vitro IL-1β secretion and association with dis-
ease course in CD and UC patients has been previously 
reported [19, 20]. So far, little is known about the func-
tional consequences of the investigated SNPs in the regu-
latory region of NLRP3. NLRP3 mRNA expression was 
lower in PBMCs isolated from carriers of the major alleles 
of rs4353135 and rs10733113 in the CD-cohorts studied 
by Villani et  al. and in patients with myocardial infarc-
tion and healthy controls [1, 13]. IL-1β secretion from 
isolated PBMCs was lower in patients with homozygous 
genotype for the major allele (GG) of SNP rs6672995 
[1] and the same trend could be observed for homozy-
gous genotype for the major alleles of rs55646866 and 
rs10733113. Homozygous genotype for the minor allele 
of rs4353135 was further associated with a higher risk 
for oligoarticular and polyarticular juvenile idiopathic 
arthritis and higher levels of inflammatory markers in a 
Taiwanese population [21], while presence of the G-allele 
of rs10733113 was associated with early onset disease in 
psoriatic arthritis [22].
These findings suggest that the NLRP3 polymorphisms 
that are associated with CD might lead to lower NLRP3-
inflammasome activity and lower IL-1β secretion. In line 
with the proposed pro-inflammatory role for NLRP3 and 
IL-1β, such lower NLRP3 activity and IL-1β secretion, 
might indeed be causally related to a less severe disease 
course resulting in a lower CDAI in CD patients homozy-
gous for the major allele for these SNPs. As we observed 
a cumulative effect of the investigated NLRP3 variants 
on CDAI it would be of particular interest to investigate 
whether being homozygous for the major allele for more 
than one of the investigated SNPs has a cumulative effect 
on IL-1β secretion, thus that patients homozygous for 
all three major alleles would have the lowest IL-1β lev-
els. Furthermore, polymorphisms in the IL1B gene have 
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**
Fig. 2 Individual and cumulative effect of the major alleles of rs10733113, rs4353135 and rs55646866 on ambulatory flare management in UC 
patients. The graphs show the percentage of UC patients with at least one ambulatory visit for flare management A Homozygous for the major 
allele, heterozygous or homozygous for the minor allele for rs10733113, rs4353135 and rs55646866. B Depending on the cumulative genetic 
risk score for carrying the major allele for rs10733113, rs4353135 and rs55646866. In a linear regression model a significant association between 
the cumulative genetic score and the percentage of patients needing ambulatory flare management could be observed (Odds ratio 2.081; 95% 
CI − 1.393 to 3.11; p < 0.001). C Age at disease onset is shown within the 25% and 75% percentile (box borders) and outliers (dots) in UC patients.
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been reported to affect course and severity of IBD [23] 
and nucleotide-binding domain and leucine-rich repeat 
caspase recruitment domain 4 (NLRC4) and NLRP3 can 
be recruited to the same macromolecular inflamma-
some complex [24]. Although no associations between 
NLCR4 or CASP1 polymorphisms and IBD have been 
reported so far, it would be very interesting to investigate 
whether IL-1β levels are affected by cumulative effects of 
polymorphisms in IL1B itself and further genes involved 
in IL-1β processing. Unfortunately, such an analysis is 
beyond the scope of our study.
CD and UC are distinct clinical entities with differ-
ences in disease location, histology and only partly 
shared genetic susceptibility [25]. Still, the diverging 
effect of CD-associated NLRP3 polymorphisms on dis-
ease characteristics in CD patients and UC patients is 
striking, as similarly elevated secretion levels of IL-1β 
have been observed in CD and UC patients [4–6, 8, 26]. 
The diverging role of NLRP3 polymorphisms on clinical 
parameters in CD and UC patients remains unexplained 
and the role of NLRP3 and IL-1β in IBD is still elusive, 
as reviewed in detail recently [27]. Although consistently 
elevated levels of IL-1β secretion have been reported for 
both CD and UC patients, IL-1β does not seem to play a 
decisive role in the inflammatory process of IBD patients, 
as only patients with IL-10R deficiency responded to IL-
1R-antagonist treatment [27]. Data from murine mod-
els of experimental colitis with animals lacking NLRP3 
show diverging effects depending on the model, experi-
mental conditions and environment. Both, aggravated as 
well as less severe course of disease have been reported 
for Nlrp3−/− mice during acute DSS and TNBS colitis [9, 
Table 6 Demographic and clinical characteristics for the different genotypes of rs10733113 in UC patients
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10, 12, 28, 29]. Itani et al. describe a more severe course 
of disease of Nlrp3−/− mice during oxazolone colitis 
[11], while Mak’Anyengo et  al. observed reduced colitis 
in Nlrp3−/− with the T-cell transfer colitis model [30]. 
These findings may be explained by the different roles 
of IL-β during intestinal inflammation: Mak’Anyengo 
et  al. showed NLRP3 dependent IL-1β promoted Th17 
differentiation and GM-CSF production of T-cells act-
ing pro-inflammatory and resulting in aggravated colitis. 
Bersudsky et  al. on the other hand, demonstrated that 
not IL-1β but IL-1α is the decisive pro-inflammatory 
mediator in the DSS colitis model, whereas IL-1β sup-
ports epithelial cell proliferation and restoration of colon 
barrier [31].
Data from patients or animals with NLRP3 hyper-
activity provide a similar controversial picture for the 
role of NLRP3 in colitis. Both aggravation as well as ame-
lioration of colitis have been shown in patients and mice 
with various reasons of NLRP3 hyperactivation. Lack of 
negative regulation by IL-10 leads to NLRP3 overactiva-
tion in Il10−/− mice that develop spontaneous colitis [32, 
33]. In this model the pro-inflammatory role of IL-1β 
seems to be non-redundant as treatment with a CASP1 
or a NLRP3 inhibitor ameliorated established disease 
and prevented or delayed development of spontaneous 
colitis. Similarly, lack of negative regulation of NLRP3 by 
mutated CARD8 was found to be responsible for devel-
opment of CD in three related patients, as disease was 
responsive to IL-1β inhibition [34].
On the contrary, situations with protective effects of 
NLRP3 hyperactivation have been observed in mice car-
rying an activating, autoimmune-associated mutation of 
Table 7 Demographic and clinical characteristics for the different genotypes of rs4353135 in UC patients
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Ptpn22 [29]. As NLRP3 is activated by PTPN22-dephos-
phorylation, the Ptpn619W variant leads to increased 
NLRP3 activation and IL-1β secretion. Mice carrying 
this mutation were protected from DSS colitis. Likewise, 
mice carrying the same activating mutation (Nlrp3R258W) 
that is responsible for increased NLRP3 activation and 
IL-1β levels in patients with cryoporin associated peri-
odic syndrome (CAPS) were resistant to DSS colitis and 
T cell transfer colitis [35]. In these animals NLRP3 hyper-
activation led to remodelling of the gut microbiota and 
increased production of regulatory T cells and antimicro-
bial peptides.
As gut microbiota alterations have been reported 
for animal models of both lack [10] or hyperactivation 
[35] of NLRP3, the question arises, whether NLRP3 
variant induced modulation of the gut microbiota 
might be involved in the effect on IBD disease course. 
Yet, Yilmaz et  al. [36] performed an extensive analysis 
of microbiota disturbances in the SIBDCS, but did not 
report effects of polymorphisms and we are not aware of 
any other study investigating the impact of NLRP3 SNPs 
on the gut microbiota.
So far, it is not clear whether polymorphisms that affect 
IBD risk also contribute to disease course and severity. 
While O’Donnell et al. [37] report association of 8 SNPs 
with time to-abdominal surgery, Lee et  al. [38] could 
not identify any associations of disease susceptibility 
loci with disease prognosis, but identified four loci with 
significant association to the course of CD without any 
association to disease susceptibility. In addition, TLR 
Table 8 Demographic and clinical characteristics for the different genotypes of rs55646866 in UC patients











 Male (n = 369)





























 No (n = 286)



















 No (n = 284)








Flare possibly or highly related to (focus on yes):
 NSAIDs
 Antibiotics

















































Focus on the hospitalizations:








Page 14 of 16Yoganathan et al. BMC Gastroenterol          (2021) 21:310 
SNPs that do not affect disease susceptibility, were found 
to be associated with extensive colonic disease in both 
CD and UC patients [39], and polymorphisms associated 
with smoking behavior could predict the number of sur-
geries and the time to first intestinal surgery in smoking 
Crohn’s disease patients [40].
Studies addressing the association of genetic loci to 
disease prognosis included a smaller number of patients 
in contrast  to large genome wide association studies 
addressing IBD risk. We here studied 981 CD and 690 UC 
patients leading to significant associations, not robust to 
Bonferroni correction. Therefore, the identified associa-
tions between NLRP3 polymorphisms and IBD prognosis 
need to be confirmed in additional cohorts.
Based on the currently available (sparse) data, that 
homozygous genotype for the major allele of CD associ-
ated NLRP3 variants leads to lower NLRP3 mRNA levels 
and activity resulting in lower IL-1β secretion, our find-
ings suggest that during established CD the pro-inflam-
matory role of IL-1β might dominate, thus that patients 
homozygous for the major allele of these SNPs might 
profit from a less severe course of disease. In UC patients 
on the other hand, our findings support a protective role 
of NLRP3 such that homozygous genotype for the major 
alleles of the investigated NLRP3 polymorphisms might 
favour a more severe course of disease.
The fact, that the major alleles of NLRP3 polymor-
phisms are the CD associated alleles implies that a 
considerable number of CD patients—in our study 43%—
might profit from the beneficial effect on disease severity. 
On the other hand, in CD patients homozygous for the 
minor allele, potentially resulting in a more active NLRP3 
inflammasome, newly available NLRP3 inhibitors, e.g. 
MCC950 or Cy-09 [41, 42] might present a novel treat-
ment option. In contrast, based on our findings that the 
major alleles of CD-associated NLRP3 variants were 
associated with more days of hospitalization in UC 
patients, treatment with NLRP3 inhibitors might be det-
rimental in UC patients. Nevertheless, a detailed analysis 
of the effects of NLRP3 variants on NLRP3-inflammas-
ome activity and on IL-1β cytokine levels in IBD patients 
is necessary, before considering NLRP3 variant data for 
treatment decisions.
Conclusions
In summary, we here show that SNPs in the regulatory 
region of the NLRP3 gene have diverging effects on the 
course of disease in CD and UC patients. Our findings 
should be taken into account, if treatment with novel 
NLRP3 inhibitors is considered. Yet, further confirma-
tion of the impact of NLRP3 polymorphisms on IBD 
disease course in additional and/or larger cohorts and 
a more detailed analysis of the consequences of NLRP3 
variants is necessary.
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